Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nyxoah to ParticipateinthePiper Sandler 34th AnnualHealthcare Conference
Mont-Saint-Guibert, Belgium –November 17, 2022, 10:30pm CET / 4:30pmET – NyxoahSA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022, at the Lotte New York Palace hotel in New York.
Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update during a fireside chat on Thursday, December 1, 2022, at 12:00pm ET. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1x1 meetings with institutional investors attending the event.
Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab25.4.2024 04:11:25 CEST | Press release
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combina
Net Income of R$ 55.3 mm in 1Q24, a 90.1% Increase YOY and Leases EBITDA Margin of 72.1%25.4.2024 02:58:18 CEST | Press release
On track to deliver 2024 Record Production of 500,000 sqm of GLA BELO HORIZONTE, Brazil, April 24, 2024 (GLOBE NEWSWIRE) -- Log Commercial Properties (B3: LOGG3), a leading developer of greenfield assets and lessor of Class A logistics warehouses in Brazil, is pleased to announce its financial results for the first quarter. 1Q24 Operational Highlights: Deliveries totaling 57,000 sqm of GLA were completed with a 100% pre-lease rateMilestone of 2.0 million sqm of GLA historically delivered by the CompanyGross absorption of 134,000 sqm of GLAStabilized vacancy of 0.91%,Same Client Rent of 1,9%, above inflation for the 7th consecutive quarter 1Q24 Financial Highlights: Strong EBITDA of R$ 74.0 million in 1Q24, with a growth of 36.4%EBITDA from leases of R$ 38.8 million and a margin of 72.1% in 1Q24Asset recycling of R$ 1.7 billion in the last 12 monthsAdjusted net debt reduction of 37.4%, totaling R$ 744.3 million in 1Q24Adjusted leverage of 0.8x considering the asset sales in April Manage
Elavon and FreedomPay to transform payments for hospitality and retail in Europe25.4.2024 01:01:00 CEST | Press release
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Elavon, a leading global payments provider, today announces its expanded collaboration in Europe with FreedomPay, a global leader in Next Level Commerce™ technologies. The partnership aims to deliver cutting-edge integrated commerce solutions and omni-channel payments technology to large enterprise merchants across Retail and Hospitality. The agreement pairs Elavon acquiring with FreedomPay commerce technologies to benefit Elavon merchants across Europe, empowering businesses with enhanced payment flexibility and optionality, data security, and a seamlessly integrated payments technology across both physical and ecommerce channels. “Elavon and FreedomPay have an enviable track record in Europe of helping hospitality and retail merchants grow their operations and better meet their customers’ needs,” said Hemlata Narasimhan, President of Elavon in Europe. “We’re pleased to extend our relationship with FreedomPay to continue to offer the first-cl
Ensurge Micropower ASA - Grant of Incentive Subscription Rights24.4.2024 23:30:00 CEST | Press release
The Board of Directors of Ensurge Micropower ASA (the "Company") resolved on 24 April 2024 to issue a total of 202,200 incentive subscription rights to employees in the Ensurge group. The grants were made under the Company's 2023 incentive subscription rights plan, as resolved at the Annual General Meeting on 24 May 2023, and amended on the Extraordinary General Meeting held on 10 November 2023. The exercise price of the subscription rights is calculated to NOK 1.2640 per share. The subscription rights expire on 24 May 2028. The subscription rights follow the terms and conditions of the 2023 subscription rights incentive plan. Following the grant there are 46,057,881 incentive subscription rights issued and outstanding in the Company. For more information, please contact: Lars Eikeland, Chief Executive Officer E- mail: lars.eikeland@ensurge.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bombardier Unveils Bold New Brand Identity Worldwide as Company Soars Toward an Ambitious Future24.4.2024 23:12:07 CEST | Press release
A new logo celebrates the company’s successful shift toward pure-play business aviation. The symbol itself, the Bombardier Mach, features the silhouette of an aircraft breaking the sound barrier, while the strokes of wind over a wing reference the company’s heritageThe employee value proposition “where heart meets mastery” focuses on Bombardier’s talented people, celebrating the workforce’s renowned passion, its incredible craftsmanship and profound technological expertise MONTRÉAL, April 24, 2024 (GLOBE NEWSWIRE) -- Bombardier, the worldwide leader in business aviation, today unveiled a new brand identity anchored by the evolution of the company’s logo. As Bombardier successfully moves forward as a company with a sole focus on designing, building and servicing the world’s best business jets, the new brand identity will reinforce and propel the company’s unique approach to its customers and stakeholders—putting people at the centre and instilling a one-of-a-kind sense of family. Bombar